Research article
Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use

https://doi.org/10.1016/0022-510X(94)90237-2Get rights and content

Abstract

Treatments by oral administration of chenodeoxycholic acid (CDCA) alone, 3-hydroxy-3-methylglutaryl (HMG) CoA reductase inhibitor (pravastatin) alone, and combination of the two drugs were attempted for 7 patients with cerebrotendinous xanthomatosis (CTX). CDCA treatment at a dose of 300 mg/day reduced serum cholestanol (67.3% reduction), lathosterol (50.8%), campesterol (61.7%) and sitosterol (12.7%). However, the sera of the patients changed to be “atherogenic”; total cholesterol, triglyceride and low-density lipoprotein (LDL)-cholesterol were increased, while high-density lipoprotein (HDL)-cholesterol was decreased. Contrarily, pravastatin at a dose of 10 mg/day improved the sera of the patients to be markedly “anti-atherogenic”, but the reductions of cholestanol (30.4%), lathosterol (44.0%), campesterol (22.9%) and sitosterol (9.6%) were inadequate. Combined treatment with CDCA and pravastatin showed good overlapping of the effects of each drug alone. The sera of the patients were apparently more “anti-atherogenic” than those after CDCA treatment. Serum cholestanol concentration was still 2.7 times higher than in controls, but the serum lathosterol level was within the normal range, indicating that the enhancement of overall cholesterol synthesis in the patients was sufficiently suppressed. Plant sterol levels were also within the normal range. The combination of CDCA and pravastatin was a good treatment for CTX, based on the improvement of serum lipoprotein metabolism, the suppression of cholesterol synthesis, and reductions of cholestanol and plant sterol levels. In all of 7 patients, the progression of disease was arrested, but dramatic effects on clinical manifestations, xanthoma, and electrophysiological findings could not be found after the treatment of these drugs.

References (41)

  • T. Nakamura et al.

    Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthoma in cerebrotendinous xanthomatosis

    Metabolism

    (1991)
  • G. Nicolau et al.

    Determination of hepatic 3-hydroxy-3-methylglutaryl Co A reductase activity in man

    J. Lipid Res.

    (1974)
  • G. Salen et al.

    Chenodeoxycholic acid inhibits increased cholesterol and cholestanol synthesis in patients with cerebrotendinous xanthomatosis

    Biochem. Med.

    (1975)
  • G. Salen et al.

    Transformation of 4-cholesten-3-one and 7-hydroxy-4-cholesten-3-one into cholestanol and bile acids in CTX

    Gastroenterology

    (1984)
  • S. Skrede et al.

    Hepatic 7-dehydroxylation of bile acid intermediates, and its significance for the pathogenesis of cerebrotendinous xanthomatosis

    J. Lipid Res.

    (1988)
  • G.S. Tint et al.

    Chenodeoxycholic acid normalized elevated lipoprotein secretion and catabolism in cerebrotendinous xanthomatosis

    J. Lipid Res.

    (1989)
  • B.G. Wolthers et al.

    Reduction of urinary bile alcohol excretion and serum cholestanol in patients with cerebrotendinous xanthomatosis after oral administration of cholic acid

    Clin. Chim. Acta

    (1990)
  • V.M. Berginer et al.

    Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid

    New Engl. J. Med.

    (1984)
  • I. Björkhem et al.

    Role of the 26-hydroxylase in the biosynthesis of bile acids in the normal state and in cerebrotendinous xanthomatosis: an in vivo study

    J. Clin. Invest.

    (1983)
  • I. Björkhem et al.

    Familial diseases with storage of sterols other than cholesterol: cerebrotendinous xanthomatosis

  • Cited by (0)

    View full text